Application of the "Haemoblock" in Pacemaker Patients

NCT ID: NCT04559646

Last Updated: 2023-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2023-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pocket hematoma is a known complication of pacemaker (PM) implantation. Pocket hematoma is accompanied by a local discomfort associated with the infiltration of subcutaneous tissue. In some cases, this complication requires repeated surgical revisions, which increases the risk of infection, and increases the duration of a hospital stay. The search for ways to prevent bleeding from the PM pocket is of great practical interest. This question is especially acute in relation to patients who are constantly on anticoagulation and/or antiplatelet therapy. A number of authors propose to carry out complete or partial cancellation of these drugs for the period before surgery and in the early postoperative period. In our opinion, this approach in most cases carries a potential risk to the health of patients, especially in the case of patients who have previously undergone surgical correction of valve insufficiency and/or who have undergone percutaneous endovascular interventions.

The use of local hemostatic drugs is one of the promising directions for increasing the efficiency of intraoperative hemostasis. The haemostatic solution "Haemoblock" has shown its hemostatic potential in general surgical practice. The possibilities of "Haemoblock" in the prevention of pocket hematoma have not been studied. The hemostatic effect of "Haemoblock" is achieved within 1-2 minutes due to the formation of a clot with blood plasma proteins, first of all with albumin. As a result of the action of the "Haemoblock", a strong polymethacrylate membrane is formed on the surface of the wound, which, among other things, has a bactericidal effect.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

А multicenter research trial will be conducted at 6 medical centers:

* Ryazan State Medical University (Ryazan);
* Federal State Budgetary Institution "Federal Center for Cardiovascular Surgery" of the Ministry of Health of the Russian Federation (Astrakhan);
* Federal State Budgetary Institution "Federal Center for Cardiovascular Surgery" of the Ministry of Health of the Russian Federation (Penza);
* Federal State Budgetary Institution "Federal Center for Cardiovascular Surgery" of the Ministry of Health of the Russian Federation (Chelyabinsk);
* Federal State Budgetary Institution "Federal Center for Cardiovascular Surgery" of the Ministry of Health of the Russian Federation (Kaliningrad);
* Federal State Budgetary Institution "Federal Center for Cardiovascular Surgery" of the Ministry of Health of the Russian Federation (Khabarovsk).

Haemostatic solution "Haemoblock" provided by Autonomous non-profit organization "MOSCOW REGIONAL SCIENTIFIC RESEARCH INSTITUTE OF BLOOD".

The study will include 200 patients with indications for pacemaker implantation (atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other).

Before starting the study, the patient must give written consent to participate in this study after familiarizing him with the purpose and rules of the clinical study.

All patients during randomisation will be divided into 2 groups:

Group A "Haemoblock" - 100 patients. Haemostatic solution "Haemoblock" will be used after pocket formation during pacemaker implantation (sterile gauze swabs are soaked in 15 ml of "Haemoblock" solution and applied in pacemaker pocket, then pacemaker pocket will be irrigated with 5 ml of "Haemoblock" solution without rinsing).

Group B "Control" - 100 patients. Same procedure will be performed with saline solution in this group.

Before surgery blood sampling, echocardiography will be performed in all patients.

3-5 days after surgery ultrasound of pacemaker pocket will be performed in all patients.

The observation period for patients will be 30 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematoma Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A "Haemoblock"

100 patients. Haemostatic solution "Haemoblock" will be used after pocket formation during pacemaker implantation.

Pacemaker implantation

Intervention Type PROCEDURE

Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.

Haemostatic solution "Haemoblock" application

Intervention Type DRUG

Haemostatic solution "Haemoblock" will be used after pocket formation during pacemaker implantation.

Ultrasound of pacemaker pocket

Intervention Type DIAGNOSTIC_TEST

Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.

Blood sampling

Intervention Type DIAGNOSTIC_TEST

Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.

Echocardiography

Intervention Type DIAGNOSTIC_TEST

Heart ultrasound examination for left ventricular ejection fraction measurement.

Group B "Control"

100 patients. Saline solution will be used after pocket formation during pacemaker implantation.

Pacemaker implantation

Intervention Type PROCEDURE

Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.

Saline solution application

Intervention Type DRUG

Saline solution will be used after pocket formation during pacemaker implantation.

Ultrasound of pacemaker pocket

Intervention Type DIAGNOSTIC_TEST

Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.

Blood sampling

Intervention Type DIAGNOSTIC_TEST

Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.

Echocardiography

Intervention Type DIAGNOSTIC_TEST

Heart ultrasound examination for left ventricular ejection fraction measurement.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pacemaker implantation

Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.

Intervention Type PROCEDURE

Haemostatic solution "Haemoblock" application

Haemostatic solution "Haemoblock" will be used after pocket formation during pacemaker implantation.

Intervention Type DRUG

Saline solution application

Saline solution will be used after pocket formation during pacemaker implantation.

Intervention Type DRUG

Ultrasound of pacemaker pocket

Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.

Intervention Type DIAGNOSTIC_TEST

Blood sampling

Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.

Intervention Type DIAGNOSTIC_TEST

Echocardiography

Heart ultrasound examination for left ventricular ejection fraction measurement.

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

"Haemoblock" application Saline application

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* availability of informed consent of the patient to participate in the study;
* men and women aged 40-85 years with indications for pacemaker implantation, taking oral anticoagulants before surgery for at least 7 days;

Exclusion Criteria

* hypoalbuminemia;
* known contraindications for the study haemostatic solution "Haemoblock";
* severe arterial hypertension: Systolic blood pressure ≥ 200 mmHg and/or Diastolic blood pressure ≥ 110 mmHg;
* unstable forms of ischemic heart disease;
* hemostasis disorders in the number of platelets, prothrombin, fibrinogen levels, or International Normalised Ratio above 3.0
* LVEF according to Simpson \<35%;
* the period of pregnancy and lactation;
* chronic renal failure: creatinine clearance less than 40 ml/min;
* hemoglobin level \<90 g/l;
* participation in another study.
Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ryazan State Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Igor A. Suchkov, MD, DSc

Role: PRINCIPAL_INVESTIGATOR

Ryazan State Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ryazan State Medical University

Ryazan, Ryazan Oblast, Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PEGASUS2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AI-Guided Left Bundle Branch Area Pacing
NCT07206602 NOT_YET_RECRUITING NA
The Boston Pace Study
NCT05869500 UNKNOWN NA